JuniorSTAR™ insulin pen designed to help young people living with diabetes take greater control of their lives

 JuniorSTAR™ insulin pen designed to help young people living with diabetes  take greater control of their lives  MONTREAL, July 2, 2014 /CNW/ - Kids with Type 1 Diabetes (T1D) face many  difficulties and challenges, including learning to self-inject. But now a new  insulin pen from Sanofi Canada has been designed to help these youngsters  through the process.  JuniorSTAR(™), available across Canada, has been developed for ease of use.  A recent survey found that JuniorSTAR(™) is well suited to the lifestyle of  young people with T1D and "could help them to gain autonomy to self-inject."(1)  This is important, since controlling their T1D is the first step in enabling  people to become empowered. "These kids go through a lot - emotionally,  socially, and psychologically," said Martin Arès, Sanofi Canada's  Vice-President, Diabetes Patient-Centered Unit. "By making it easier for them  to manage, giving them greater control, JuniorSTAR(™) can make a positive  difference."  In Canada, more than 300,000 individuals have T1D and the number is growing  every year.(2) T1D usually develops in childhood or adolescence.(3) It is an  autoimmune disease in which the body's immune system attacks and destroys the  insulin-producing cells of the pancreas, thereby leaving the individual  dependent on an external source of insulin for life.  Living with T1D requires constant vigilance. People with the disease must  carefully balance insulin doses (either by injections multiple times a day or  continuous infusion through a pump) with eating and daily activities. They  must also test their blood sugar by pricking their fingers six or more times a  day. Despite this constant attention, people with T1D still run the risk of  dangerously high or low blood sugar levels, both of which can be  life-threatening.(4) *  ____________________________ (1) Klonoff D et al., Evaluation of the  JuniorSTAR® Half-unit Insulin Pen in Young People with Type 1 Diabetes - User  Perspectives, European Endocrinology, 2013; 9(2):82-5 (2) Canadian Diabetes  Association, The prevalence and costs of diabetes, December 2009.  (3)  Canadian Diabetes Association  http://www.diabetes.ca/documents/get-involved/WEB_Eng.CDA_Report_.pdf (4) JDRF  http://www.jdrf.ca/news-and-media/fact-sheets/type-1-diabetes/ * As per the  CDA guidelines: For individuals using insulin more than once a day, SMBG  should be measured as an essential part of diabetes self-management and should  be undertaken at least 3 times per day and include both pre- and postprandial  measurements. http://guidelines.diabetes.ca/executivesummary/ch9#bib1  For parents and young patients, especially, T1D can be overwhelming. "It  definitely has a big impact on their lives and emotional well-being,"  explained Marlene Grass RN, a Nurse Educator in Durham Region specializing in  T1D. "They may be self-conscious, worried about body image, feeling socially  excluded, angry and may have depressed feelings. It may affect how well they  do in school. It has an impact on their family and caregivers as well."  She added: "That's why it's so important to empower these youngsters, to help  them gain greater independence in performing their diabetes procedures, under  adult supervision, and having a feeling of more control over their lives. It  is also reassuring for parents who are very concerned about the health and  wellbeing of their children. JuniorSTAR(™ )is an insulin injection pen that  helps facilitate this."  The key features of JuniorSTAR(™) are:        --  doses can be adjusted in half-units - meeting the requirements         of younger patients     --  the dosage display is large - easy to read     --  it's lightweight (only 34 grams) - easy to carry     --  the outer body is made of aluminum - can withstand kids' active         lives     --  there are two different coloured pens - to help avoid insulin         mix-up     --  there is a single step dial-back - mistakes can be easily         corrected  Children frequently make mistakes when self-administering insulin. A device  that makes the process easier and simpler will help them avoid errors, improve  their dose dialing accuracy, and give them greater confidence.  "T1D is often difficult. It takes an emotional toll. It is life-threatening.  And it never goes away," said Julien Oakes, a person living with T1D. "But we  can learn to successfully manage the disease, and with the support of  resources such as JuniorSTAR(™), we can get on with living a normal life and  achieving our goals."  About Sanofi Sanofi, a global healthcare leader, discovers, develops and  distributes therapeutic solutions focused on patients' needs. Sanofi has core  strengths in the field of healthcare with seven growth platforms: diabetes  solutions, human vaccines, innovative drugs, consumer healthcare, emerging  markets, animal health and the new Genzyme. Sanofi is listed in Paris  (EURONEXT: SAN) and in New York (NYSE: SNY).  Sanofi entities in Canada include Sanofi Canada (pharmaceuticals), Sanofi  Pasteur (vaccines), Sanofi Consumer Health (cosmeceuticals, over-the-counter  products and specialty care), Genzyme (rare diseases) and Merial (animal  health). Together they employ close to 1,700 people across the country. In  2013 Sanofi companies invested $125,1 million in R&D in Canada, creating jobs,  business and opportunity throughout the country. www.sanofi.ca  Follow Sanofi Canada on Twitter @SanofiCanada.  Video and photos are available on request. Go to starsystem.sanofi.ca for  further information.     SOURCE  Sanofi Canada  For interviews, contact: Toronto, Niki Kerimova, office: 416-777-0368, cell:  647-278-3375, niki@prpost.ca; Montreal, Lamia Charlebois, office:  514-279-4601, cell.: 514-581-5831, rp@lamiacharlebois.com  To view this news release in HTML formatting, please use the following URL:  http://www.newswire.ca/en/releases/archive/July2014/02/c3022.html  CO: Sanofi Canada ST: Quebec NI: HEA MTC NP  
Press spacebar to pause and continue. Press esc to stop.